Nghiên cứu hiệu quả điều trị rối loạn lipid máu của liệu pháp statin ở bệnh nhân tăng huyết áp phân tầng nguy cơ tim mạch cao

Abstract

Many studies have shown that treatment of dyslipidemia with statins is effective in reducing cardiovascular morbidity and mortality in hypertensive patients. This study aimed to evaluate the effectiveness of statin therapy in treating dyslipidemia in hypertensive patients with high cardiovascular risk stratification; the study was conducted on 105 eligible patients at the Department of Cardiology, Hue Central Hospital, from May 2022 to May 2024. After 6 weeks, high-intensity statin therapy reduced mean TP Cholesterol by -25.5% (compared to -16.3% in the low-moderate group) and LDL-C by -30.4% (compared to -20.9%, respectively). In the high-intensity statin group, Rosuvastatin 20mg reduced TP Cholesterol by -27.82% compared to Atorvastatin 40mg by -22.84% and LDL-C by -33.07% compared to -29.35%. Logistic regression analysis showed that pre-treatment LDL-C level was an independent factor affecting the ability to achieve LDL-C goals (p < 0.001). There were no serious side effect such as increased liver enzymes or CK beyond the limit in either group.